Similar to other gastrointestinal tumors, overexpression of EGFR is reported in more than 60% of pancreatic cancers and 30–60% of cholangiocarcinoma patients based on immunohistochemical analysis [59,163,164]. Here, EGFR is linked to pancreatic neoplasm.